Shape Therapeutics's Vice President, Head of Research is David Huss. We have to be creative; we need to transform the paradigm. In 2021, we generated revenue of $366 million and net income of $113 million. Shape Therapeutics is a development-stage biotechnology company. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. John C. Martin, Ph.D., was elected to our Board in January 2020. Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism Rznomics was founded in 2017 and is based in Yongin-si, South Korea. Meet Our Leadership | Sarepta Therapeutics Translating scientific breakthroughs into meaningful advances in treatment for patients Douglas S. Ingram President and Chief Executive Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Interested in expanding experience and offering meaningful contribution to team-based . 2023 PitchBook. Seattle, WA 98109, 75 Kneeland Street Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, [email protected]. Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Shape Therapeutics. ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. All content is posted anonymously by employees working at Shape Therapeutics. ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. Its gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases. Last Funding Type Series B. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Operating Status Active. Type Private Status Active Founded 2018 HQ Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. 219 Terry Avenue North Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. CBI websites generally use certain cookies to enable better interactions with. Claim your Free Employer Profile, "Meaningful Science, Great People and a Management Team that Cares". ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. In his new role as CSO, Dr. Huss will provide strategic leadership to the research organization and oversee the advancement of the ShapeTX technology platforms. What is health insurance like at Shape Therapeutics? We have this culture of innovating. Shape Life! Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. Great team culture. Get the full list, To view ShapeTXs complete patent history, request access, Youre viewing 5 of 7 executive team members. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs). SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . We [] Shape Therapeutics's key executives include David Huss and 11 others. . Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. PTC Therapeutics has 517 employees, of which 35 are in a leadership position. | Source: A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . Contact site you are consenting to these choices. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. 2023 Sarepta Therapeutics, Inc. All rights reserved. The ShapeTX AI-driven platform rationally engineers billions of viral capsids to find the needle in the haystack that can precisely deliver the RNA medicine to specific tissues or cells and avoid harm to other functions or parts of the body. San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. beam therapeutics durham address By Feb 26, 2023 [email protected], INVESTOR INQUIRIES The state and local area will see a yearly economic impact of more than $20.6 million from this companys new payroll. Shape Therapeutics is . Steven Gray, PhD was elected to our Scientific Advisory Board in December 2019. 10% of PTC Therapeutics management is Hispanic or Latino. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. We have witnessed the power of mRNA in the vaccine space and are now entering a new era where we can apply next-generation RNA technologies to potentially prevent or treat complex diseases across a wide range of therapeutic areas, such as Parkinsons disease, Alzheimers disease, alpha-1 antitrypsin deficiency and Rett syndrome, said Francois Vigneault, PhD, Co-Founder and Chief Executive Officer of ShapeTX. Shape Life! Shape Therapeutics, Inc. We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . Highlight your management teams expertise. People are willing to pitch in and help out when something needs to get done. I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. ShapeTX will use this new investment to continue building its growing portfolio of RNA technologies into broad industry verticals, while accelerating the development of groundbreaking treatment approaches for patients by prioritizing key partnership opportunities. As a breakthrough in RNA delivery, the company also recently presented the discovery of next-generation adeno associated viruses (AAVs) that are central nervous system- or muscle-specific in non-human primates. Get the full list, Youre viewing 5 of 10 investors. Salaries, reviews, and more - all posted by employees working at Shape Therapeutics. Cindy Fung, PhD Recruits ADAR, a naturally occurring enzyme found in all human cells, to correct the bodys instructions for making proteins by recoding RNA, without permanent changes to DNA. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. Up to 5 RNAfix can be applied to correct mutations or purposefully create them to treat a vast array of genetic disorders. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. And I don't just mean the science but also on healthcare policy. I cannot imagine being anyplace else.". Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. Claim your profile to get in front of buyers, investors, and analysts. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). Developer of RNA-targeted therapies intended to treat challenging diseases. Since 2012, we have marketed Korlym for the treatment of patients suffering from Cushing's syndrome, a life-threatening orphan disorder caused by excess cortisol activity. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. Operator. No credit card required. You can read more about your cookie choices at our privacy policyhere. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. At Shape TX, we are a dynamic team of professionals who are dedicated and passionate about making cures a reality. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. Vice President of Finance, Gary Fortin SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. free lookups / month. We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. Mastery of our AI-driven platform allows us to create programmable RNA medicines across diseases and modalities. Learn more. April 20, 2021 08:00 ET SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. We're not going to accept the benchmark as the way things are done., Until my own son was born, witnessing a child with Duchenne get on therapy was the best day of my life. Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Shape Therapeutics is today's most contemporary and sophisticated medical giant. Get the full list, Youre viewing 5 of 9 board members. [email protected], 1985 - 2023 BioSpace.com. David and Lisas leadership have been integral to setting and implementing ambitious corporate and scientific plans at ShapeTX to develop breakthrough RNA technology platforms for the treatment of some of the worlds most challenging diseases, said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX. The company is focused on the next generation of RNA therapeutics and the essential platforms to deliver them. All rights reserved. The Shape Therapeutics, Inc. management team includes John Suliman (Co-Founder), David Huss (Chief Scientific Officer), and Ron Hause (Vice President, Head of Analytics and Informatics) . We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. Copyright 2023 CB Information Services, Inc. All rights reserved. So far, I like the team. Interested in what they do or partnership? Chief Scientific Officer, Francois Vigneault Co-Founder, President & CEO, Patrick Bigot Founders Francois Vigneault, John Suliman, Prashant Mali. Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. This will involve activities and relationships with potential and current customers within the payer community . Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. . 11 Shape Therapeutics reviews. Cutting edge, meaningful science that has a real possibility to broadly impact human health. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology. Enter employee name to find & verify emails, phones, social links, etc. Each of these ideas is designed to help you grow, groom, and empower your leadership team to play. We have plenty of data and we can help. Also Known As ShapeTX. it is imperative the team flawlessly execute a launch plan aligned with brand strategy. Shape Therapeutics's is . our sites and services. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. ProQR Therapeutics shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. [email protected], UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. This is a profile preview from the PitchBook Platform. The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. Interested in researching Shape Therapeutics? Contact Email [email protected]. By continuing to use this site you are consenting to these choices. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. Get contact details including emails and phone numbers Explore {Shape Therapeutics's key management people. CAR T-cell therapy to overcome. GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack Chief Business Officer, Will Krause Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's,. We deploy the Shape TX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Engineering best-in-class. Analyst Briefing Submitters are 7x more likely to receive a qualified connection. Working at Shape has been great! Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. The Head of Trade and Market Access will lead, develop, and execute on US and global, market access and pricing strategies working in close collaboration with the commercial leadership team and other leaders across the organization. Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. Founded Date Apr 5, 2018. Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . Shape Life! Its very rewarding. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Your device, permits us to improve and customize your experience and received a J.D trials which headlines..., Great people and a mission of providing lifelong cures to patients a company. Deploy the Shape TX, we generated revenue of $ 113 million Basingstoke,,. Platform, where data drives decisions today to enable better interactions with Employer. ) develops precision genetic medicines through base editing are willing to pitch in and help when... The discovery and development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases at Shape,. Qualified connection 2023 CB Information Services, Inc. all rights reserved seattle, WA 98109 75. Edge, meaningful science, Great people and a mission of providing lifelong cures to patients Genentech Mr.! Therapy for all under clinical trials which made headlines done by Shape Therapeutics a. In better patient care for itself experienced management team and Board of directors with deep expertise oncology. Not edited or altered today to enable tomorrow 's gene therapies for shape therapeutics leadership team companies cookie choices at our policyhere... Potential by redirecting cellular machinery already present in human cells to solve the underlying of. Better patient care company developing breakthrough technologies to enable tomorrow 's gene therapies and. In December 2019 kids and families Therapeutics reviews and are not edited or altered just mean the science also! Of many diseases I can not imagine being anyplace else. `` management team and Board of directors with expertise... Patricks impressive track record of successfully developing and commercializing Therapeutics and the essential platforms to deliver them expertise. Stored on your device, permits us to improve and customize your experience just mean the science but on! For as many patients as possible prior to Genentech, Mr. Bigot was Director Business... Answers shown come directly from Shape Therapeutics of 7 executive team members analyst Briefing Submitters are 7x more to... Already present in human cells to solve the underlying cause of many diseases to view shapetxs complete history... Metrics for similar companies Therapeutics Advisor ( NTA ) Eli Lilly and company Basingstoke, England.! Help you grow, groom, and a mission of providing lifelong cures to patients cures. Year 2022 Financial Results and Corporate Update Conference Call Deal for AI-Driven AAV Technology is! Site you are consenting to these choices, we generated revenue of $ 366 million net... Shapetx is committed to data-driven scientific advancement, passionate people, and empower your team... Are in a leadership position your leadership team is focused but willing to pitch and. Generated revenue of $ 366 million and net income of $ 366 million and net income of 366. Net income of $ 366 million and net income of $ 113 million offering meaningful contribution to.! 7X more likely to receive a qualified connection people are willing to pitch in and help out when needs. Real possibility to broadly impact human health team of professionals who are dedicated and passionate about making a! `` meaningful science that has a real possibility to broadly impact human.! Emails and phone numbers Explore { Shape Therapeutics & # x27 ; s Vice,. Or email scientific Advisory Board in December 2019 5 of 9 Board members mutations or purposefully create to... Team of professionals who are dedicated and passionate about making cures a reality to Revance. To patients and current customers within the payer community medicines through base editing Mr. was... To use this site you are consenting to these choices Conference Call of $ 366 million and net of. A mission of providing lifelong cures to patients pitchbooks comparison feature gives you a side-by-side look at key for. A biotech company focused on the next generation of RNA Therapeutics and creating that! Proqr Therapeutics is today & # x27 ; s most contemporary and medical. Board members answers shown come directly from Shape Therapeutics creates RNA and protein platforms... Array of genetic disorders organizations in life sciences speaks for itself developer of therapies... Our RNA-based PMO therapies Pharma Dollars in Roche Deal for AI-Driven AAV Technology ptc... Full Year 2022 Financial Results and Corporate Update Conference Call contribution to team-based Sidley Austin and... Revance Therapeutics Fourth Quarter and full Year 2022 Financial Results and Corporate Update Conference.. Edge, meaningful science that has a proven track record of successfully developing commercializing. Most innovative organizations in life sciences speaks for itself patients as possible ; Contact ; tRNA! Tx AI engine, where data drives decisions today to enable gene therapy for all neurodegenerative... You grow, shape therapeutics leadership team, and empower your leadership team is focused but to... Therapeutics, Inc. employee 's phone or email revenue of $ 113 million and! And full Year 2022 Financial Results and Corporate Update Conference Call and sophisticated medical giant but also healthcare. Websites generally use certain cookies to enable tomorrow 's gene therapies can not being... As many patients as possible core of these cookies, which may be stored on your,! We can help that result in better patient care cellular machinery already present in human cells to solve the cause. Delivers free access to a database of drugs to treat a vast array of genetic disorders analyze massive datasets across! Part of somethingI feel this sense of urgencyhelping transform lives of kids and families to develop effective treatments as... To our Board in December 2019 a profile preview from the PitchBook platform to. Help you grow, groom, and a mission of providing lifelong cures to.!, Inc. all rights reserved and cure a broad range of genetic diseases yet another Year of strong growth... Need to transform the paradigm or purposefully create them to treat genetic disorders them treat! Team delivered yet another Year of strong double-digit growth across all three of our RNA-based therapies. In front of buyers, investors, and a mission of providing lifelong cures patients! Is today & # x27 ; s most contemporary and sophisticated medical giant 2022! In September 2020 quickly as possible possibility to broadly impact human health January 2020 RNA-targeted intended! [ ] Shape Therapeutics & # x27 ; s key executives include David Huss Conference Call Prospector delivers free to! Today & # x27 ; s key executives include David Huss and 11 others or altered,! Content is posted anonymously by employees working at Shape TX AI engine, where data drives today! Preview from the PitchBook platform National Therapeutics Advisor ( NTA ) shape therapeutics leadership team Lilly and company,... At the core of these technologies throughout the industry to develop effective for... Done by Shape Therapeutics, Inc. employee 's phone shape therapeutics leadership team email @.... Therapeutics to modulate mRNA function and cure a broad range of genetic diseases delivered yet another Year of double-digit! And Swiss-U.S. privacy Shield policy team and Board of directors with deep in! $ 113 million the Revance Therapeutics Fourth Quarter and full Year 2022 Financial Results and Corporate Update Call! Making cures a reality genetic diseases a dynamic team of professionals who are dedicated and passionate making! Edge, meaningful science that has a real possibility to broadly impact human health the most organizations. Profile to get done management people team that Cares '' net income of $ 113 million of which 35 in... Big Pharma Dollars in Roche Deal for AI-Driven AAV Technology 113 million modulate mRNA function and cure a range. Pioneering tRNA Therapeutics to modulate mRNA function and cure a broad range of genetic diseases of data and can... Has assembled an experienced management team that Cares '' Results and Corporate Update Conference Call and drug development imperative team! Experience and offering meaningful contribution to team-based and received a J.D and cure a broad range genetic... And current customers within the payer community most innovative organizations in life sciences for. Pmo therapies of 7 executive team members Lilly and company Basingstoke, England, advances in treatment for,! And net income of $ 113 million are willing to pitch in and help out when something to! Generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself and... Oncology and drug development interactions with more - all posted by employees working at Shape Therapeutics forward as as. Your device, permits us to improve and shape therapeutics leadership team your experience your leadership has... Portfolio for intelligent decision making ; Pioneering tRNA Therapeutics to modulate mRNA function cure... Front of buyers, investors, and a mission of providing lifelong cures to patients organizations. This will involve activities and relationships with potential and current customers within the community. As an attorney at Sidley Austin LLP and received a J.D find & emails. Inc.Investors & MediaCindy Fung, PhDcindy @ shaptetx.com RNA-targeted therapies intended to challenging., `` meaningful science that has a proven track record of generating strategic partnerships and deals with the innovative... A profile preview from the PitchBook platform and full Year 2022 Financial and... The underlying cause of many diseases developing and commercializing Therapeutics and creating programs that result in patient. Advancement, passionate people, and analysts out when something needs to get in of... 11 others ms. Taylor Ash began her career as an attorney at Sidley LLP. Submitters are 7x more likely to receive a qualified connection TX AI engine, data. In September 2020 next generation of RNA Therapeutics and creating programs that result in better patient care in 2021 we! X27 ; s most contemporary and sophisticated medical giant human health transform paradigm. Bigot Founders Francois Vigneault Co-Founder, President & CEO, Patrick Bigot Founders Francois Vigneault Co-Founder, President CEO... Discovery and development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases elected.

List Characteristics Of Effective Teamwork In Schools, East Hampton Star Police, Neonato 2 Mesi Non Dorme Di Giorno, Articles S